Pulmonx CorpLUNG
Price$1.91

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $87.4M+4.4% YoYTTM through 30 Jun 2026
Net Income -$48.1MTTM through 30 Jun 2026
Free Cash Flow -$30.7MTTM through 30 Jun 2026

Margins

Current
Gross Margin78.0%
EBITDA Margin-51.6%
Operating Margin-63.1%
Net Margin-55.0%

Returns

-86.2%ROE
-24.0%ROA

Balance Sheet Health

Debt / Equity0.82x
Current Ratio4.91x
Net Debt-$24.3Mnet cash position
Cash & Equivalents$55.8M

Quality Metrics

Altman Z-Score-5.82
Piotroski F-Score4 / 9
FCF Margin-35.1%
Rule of 40-31.5
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $90.5M
Diluted EPS-$1.15TTM
'20'21'22'23'24'25
FY2025: $-1.33

Dividend

No dividend

Capital Allocation

R&D Spend$19.4M
Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.